Physiological and pharmacological data have shown that activation of the GLP‐1 receptors promotes insulin secretion from pancreatic beta cells and also causes weight loss and thus representing a significant pharmacological target for the treatment of type 2 diabetes (Drucker, 2018; Kanoski et al., 2016). Here, INS is linked to type 2 diabetes mellitus.